<?xml version="1.0" encoding='utf-8' ?>
<nspnews type="text">
<version>v8.0</version>
<date>2023-08-22 19:48:41</date>
<action>I</action>
<registdate>2023-08-22 19:00:11</registdate>
<modifydate>2023-08-22 19:01:03</modifydate>
<publishdate>2023-08-22 19:48:37</publishdate>
<embargo>N</embargo>
<newsid>654482</newsid>
<orgid>654384</orgid>
<language>CN</language>
<category1>21</category1>
<category2>2102</category2>
<category1_name>의학/건강</category1_name>
<category2_name>제약/바이오</category2_name>
<statusID>1</statusID>
<saleID>N</saleID>
<formatID>1</formatID>
<typeID>7</typeID>
<newsSubject><![CDATA[日东制药进军高血压治疗药物原料“贝尼地平”中国市场]]></newsSubject>
<newsSummary><![CDATA[]]></newsSummary>
<newsTag><![CDATA[日东制药,广州,Tosun Pharmaceutical,贝尼地平]]></newsTag>
<newsLinks><![CDATA[]]></newsLinks>
<news_prolog><![CDATA[(Seoul=NSP NEWS AGENCY) =]]></news_prolog>
<news1><![CDATA[日东制药决定向中国广州Tosun Pharmaceutical出口本公司的心血管系统原料药（API）“盐酸贝尼地平”。此前，日东制药已取得中国药品管理部门对贝尼地平的原料药注册及许可。

22日，日东制药表示，最近与医药品原料及中间体事业专门制药公司托森签订了贝尼地平供应等双方合作协议，正在进行进军中国市场所需的各项程序。

贝尼地平是钙通道阻断剂（CCB）系列药物，通过阻断参与血管和心脏肌肉收缩的钙离子迁移通道，扩张血管，缓解心脏负担，主要用于治疗高血压、心绞痛等药物。

根据合同，日东制药将向土船供应其生产的盐酸盐贝尼地平，土船将面向中国国内药品市场及相关企业等开展API流通和销售、当地营销等。]]></news1>
<news2_title><![CDATA[]]></news2_title>
<news2><![CDATA[]]></news2>
<news3_title><![CDATA[]]></news3_title>
<news3><![CDATA[]]></news3>
<news4_title><![CDATA[]]></news4_title>
<news4><![CDATA[]]></news4>
<news5_title><![CDATA[]]></news5_title>
<news5><![CDATA[]]></news5>
<news_epilog_info><![CDATA[]]></news_epilog_info>
<news_epilog_byline><![CDATA[By Ha-been Kwon(rnjsgkqls@nspna.com) and Da-eun Kim(ekdms8381@nspna.com)]]></news_epilog_byline>
<news_epilog><![CDATA[ⓒNSP News Agency·NSP TV. All rights reserved.]]></news_epilog>
<imageL><![CDATA[]]></imageL>
<imageP><![CDATA[]]></imageP>
<image1><![CDATA[]]></image1>
<image2><![CDATA[]]></image2>
<image3><![CDATA[]]></image3>
<image4><![CDATA[]]></image4>
<image5><![CDATA[]]></image5>
<image1_place><![CDATA[c]]></image1_place>
<image2_place><![CDATA[c]]></image2_place>
<image3_place><![CDATA[c]]></image3_place>
<image4_place><![CDATA[c]]></image4_place>
<image5_place><![CDATA[c]]></image5_place>
<image1_text><![CDATA[]]></image1_text>
<image2_text><![CDATA[]]></image2_text>
<image3_text><![CDATA[]]></image3_text>
<image4_text><![CDATA[]]></image4_text>
<image5_text><![CDATA[]]></image5_text>
<image1_source><![CDATA[]]></image1_source>
<image2_source><![CDATA[]]></image2_source>
<image3_source><![CDATA[]]></image3_source>
<image4_source><![CDATA[]]></image4_source>
<image5_source><![CDATA[]]></image5_source>
<vodSite><![CDATA[]]></vodSite>
<vodID><![CDATA[]]></vodID>
<vodTitle><![CDATA[]]></vodTitle>
<vodWidth><![CDATA[]]></vodWidth>
<vodHeight><![CDATA[]]></vodHeight>
<advertorial><![CDATA[]]></advertorial>
<location><![CDATA[Seoul]]></location>
<teamID>110</teamID>
<teamName><![CDATA[국제부]]></teamName>
<writerID>rnjsgkqls</writerID>
<writerName><![CDATA[Ha-been Kwon]]></writerName>
<writerTitle><![CDATA[Reporter]]></writerTitle>
<writerEmail><![CDATA[rnjsgkqls@nspna.com]]></writerEmail>
<writerID2>ekdms8381</writerID2>
<writerName2><![CDATA[Da-eun Kim]]></writerName2>
<writerTitle2><![CDATA[Reporter]]></writerTitle2>
<writerEmail2><![CDATA[ekdms8381@nspna.com]]></writerEmail2>
<writerID3></writerID3>
<writerName3><![CDATA[]]></writerName3>
<writerTitle3><![CDATA[]]></writerTitle3>
<writerEmail3><![CDATA[]]></writerEmail3>
</nspnews>
